The Use of Statins for Myocardial Death Prevention

The Use of Statins for Myocardial Death Prevention: From Cell to Bedside

Status

Completed

Phases

Phase 4

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00772564

Enrollment

Registered

2008-10-15

Start date

2008-08-31

Completion date

2010-08-31

Last updated

2012-05-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Myocardial Infarction

Keywords

Acute ST Elevation Myocardial Infarction

Brief summary

The administration of high dose HMG-CoA reductase inhibitors (Statins) to patients with acute ST-elevation MI (hypoxia/ischemia) who are treated with primary PCI (reoxygenation/ reperfusion) will protect their cardiomyocytes from death and thus preserve LV ejection fraction.

Interventions

DRUGAtorvastatin

Oral Atorvastatin

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

30 Years to 90 Years

Healthy volunteers

Inclusion criteria

1\. Patients suffering from acute ST elevation resulting from myocardial infarction, Killip Classification 1 and 2 will be included at-random to either group. Included subjects should be able to give their informed consent to participate in this study.

Exclusion criteria

1. The impossibility to give the required informed consent. 2. Known allergy to Atorvastatin. 3. Base line serum creatinine of 1.4 mg/dL. 4. Killip Classification 3 and 4. 5. Persisting vomiting. 6. History of previous liver disease. 7. History of previous muscle disease or rabdomyolisis. 8. Treated already with high dose atorvastatin 9. Non Compliance.

Design outcomes

Primary

Measure	Time frame
Heart EcoCardiography and specific laboratory tests	Base line, second day and 60 days after myocardial infarction

Countries

Israel

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026